T3 Pharma raises 25M CHF to advance bacterial cancer therapy through clinic
Jul 22, 2020•almost 5 years ago
Description
T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF.